Lloyd Advisory Services LLC. lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 105 shares of the medical research company’s stock after selling 31 shares during the period. Lloyd Advisory Services LLC.’s holdings in Thermo Fisher Scientific were worth $30,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in TMO. Groesbeck Investment Management Corp NJ grew its holdings in Thermo Fisher Scientific by 14.1% in the first quarter. Groesbeck Investment Management Corp NJ now owns 3,240 shares of the medical research company’s stock valued at $919,000 after purchasing an additional 400 shares during the last quarter. CVA Family Office LLC acquired a new stake in Thermo Fisher Scientific in the first quarter valued at $142,000. Optimal Asset Management Inc. grew its holdings in Thermo Fisher Scientific by 29.9% in the first quarter. Optimal Asset Management Inc. now owns 11,226 shares of the medical research company’s stock valued at $3,184,000 after purchasing an additional 2,586 shares during the last quarter. Tredje AP fonden grew its holdings in Thermo Fisher Scientific by 6.4% in the first quarter. Tredje AP fonden now owns 33,995 shares of the medical research company’s stock valued at $9,641,000 after purchasing an additional 2,054 shares during the last quarter. Finally, Coldstream Capital Management Inc. grew its holdings in Thermo Fisher Scientific by 4.9% in the first quarter. Coldstream Capital Management Inc. now owns 2,411 shares of the medical research company’s stock valued at $684,000 after purchasing an additional 113 shares during the last quarter. 87.65% of the stock is currently owned by hedge funds and other institutional investors.

TMO has been the topic of several research reports. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $345.00 to $315.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Needham & Company LLC increased their price objective on Thermo Fisher Scientific from $341.00 to $383.00 in a research note on Thursday, April 23rd. SVB Leerink increased their price objective on Thermo Fisher Scientific from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, April 23rd. Citigroup increased their price objective on Thermo Fisher Scientific from $365.00 to $390.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Finally, Robert W. Baird increased their price objective on Thermo Fisher Scientific from $340.00 to $341.00 and gave the company an “outperform” rating in a research note on Wednesday, March 4th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $353.50.

NYSE TMO traded down $2.46 during trading hours on Friday, hitting $349.30. 18,983 shares of the company’s stock were exchanged, compared to its average volume of 1,474,341. The business’s 50 day moving average is $343.85 and its 200-day moving average is $324.42. Thermo Fisher Scientific Inc. has a 12-month low of $250.21 and a 12-month high of $358.00. The firm has a market capitalization of $137.43 billion, a P/E ratio of 38.84, a price-to-earnings-growth ratio of 2.34 and a beta of 1.04. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.69 and a current ratio of 2.32.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 22nd. The medical research company reported $2.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.79 by $0.15. Thermo Fisher Scientific had a return on equity of 17.25% and a net margin of 14.31%. The firm had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6.18 billion. During the same period in the prior year, the business posted $2.81 earnings per share. The firm’s revenue for the quarter was up 1.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 11.9 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a dividend of $0.22 per share. The ex-dividend date is Friday, June 12th. This represents a $0.88 annualized dividend and a yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 7.13%.

In other news, CEO Marc N. Casper sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $349.89, for a total value of $6,997,800.00. Following the transaction, the chief executive officer now directly owns 294,946 shares in the company, valued at approximately $103,198,655.94. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $333.02, for a total value of $9,990,600.00. Following the completion of the transaction, the chief executive officer now owns 304,946 shares in the company, valued at $101,553,116.92. The disclosure for this sale can be found here. Insiders have sold 97,500 shares of company stock worth $33,044,350 over the last quarter. 0.44% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: What is the significance of the death cross?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.